Literature DB >> 28339909

IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy.

Huey-Liang Kuo1,2, Chiu-Ching Huang2, Tze-Yi Lin3, Ching-Yuang Lin1,4.   

Abstract

Background: Early stages of diabetic nephropathy (DN) are characterized by an influx of inflammatory cells. Interactions between infiltrating T cells and podocytes may play an important role in the ongoing inflammatory response and remodelling. The aim of this study was to explore the role of IL-17 and CD40 ligand (CD40L) in DN.
Methods: The study design involved a case series. Kidney biopsy samples of 69 patients with type 2 diabetes were assessed for the presence of CD4+ IL-17+ T cells. The number of CD4+ IL-17+ T cells were counted and correlated with clinical and laboratory findings. Additionally, advanced glycation end-products (AGEs) were added to cultured podocytes to imitate diabetic conditions and thus to elucidate the role of CD4+ IL-17+ T cells in renal sclerosis.
Results: CD80 expression was detected in early phases of DN but was absent during diffused glomerurosclerosis in DN kidney specimens. In DN samples, CD40 expression was not only observed in most of the infiltrating cells, but also increased in podocytes and tubular epithelial cells. CD40L is locally expressed on infiltrating cells. CD4+ IL-17+ T cells were found in DN, and the number of CD4+ IL-17+ T cells was positively correlated with the deterioration in glomerular filtration rate (GFR). IL-17A was the key cytokine produced by CD4+ IL-17+ T cells. IL-17A levels were elevated in DN renal tissue and were correlated with declining GFR. IL-17 and CD40L synergistically enhanced IL-6, monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted (RANTES), transforming growth factor beta 1 (TGF-β1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) production in vitro. AGEs induced podocyte activation with increasing expression of IL-17A, CD40 and TGF-β1 in vitro. Blockade with an anti-IL-17 monoclonal antibody reduced the expression of CD40 and TGF-β1, but increased the viability of cultured podocytes. Conclusions: IL-17 and CD40L synergistically mediate the inflammatory response and remodelling associated with tissue injury and glomerular sclerosis in DN.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  CD4+ IL-17+ T cell; CD40L; IL-17; advanced glycation end-products; diabetic nephropathy

Mesh:

Substances:

Year:  2018        PMID: 28339909     DOI: 10.1093/ndt/gfw397

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  13 in total

Review 1.  Role of the Immune System in Diabetic Kidney Disease.

Authors:  Fionnuala B Hickey; Finian Martin
Journal:  Curr Diab Rep       Date:  2018-03-12       Impact factor: 4.810

2.  Bioinformatics analysis identifies diagnostic biomarkers and their correlation with immune infiltration in diabetic nephropathy.

Authors:  Menglan Huang; Zhengxi Zhu; Cong Nong; Zhao Liang; Jingxue Ma; Guangzhi Li
Journal:  Ann Transl Med       Date:  2022-06

3.  Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Authors:  Sophie Glatt; Dominique Baeten; Terry Baker; Meryn Griffiths; Lucian Ionescu; Alastair D G Lawson; Ash Maroof; Ruth Oliver; Serghei Popa; Foteini Strimenopoulou; Pavan Vajjah; Mark I L Watling; Nataliya Yeremenko; Pierre Miossec; Stevan Shaw
Journal:  Ann Rheum Dis       Date:  2017-12-23       Impact factor: 19.103

4.  Interleukin 17A promotes diabetic kidney injury.

Authors:  Jin Ma; Yan J Li; Xiaochen Chen; Tony Kwan; Steven J Chadban; Huiling Wu
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

5.  Shen-Kang protects against tacrolimus-induced renal injury.

Authors:  Long Ye Zhang; Jian Jin; Kang Luo; Shang Guo Piao; Hai Lan Zheng; Ji Zhe Jin; Sun Woo Lim; Bum Soon Choi; Chul Woo Yang; Can Li
Journal:  Korean J Intern Med       Date:  2018-02-12       Impact factor: 2.884

Review 6.  The CD40-ATP-P2X 7 Receptor Pathway: Cell to Cell Cross-Talk to Promote Inflammation and Programmed Cell Death of Endothelial Cells.

Authors:  Carlos S Subauste
Journal:  Front Immunol       Date:  2019-12-17       Impact factor: 7.561

7.  Using Network Pharmacology to Explore the Mechanism of Peach Kernel-Safflower in the Treatment of Diabetic Nephropathy.

Authors:  Jingxue Han; Xinwei Wang; Jingyi Hou; Yu Liu; Peng Liu; Tingting Zhao
Journal:  Biomed Res Int       Date:  2021-02-01       Impact factor: 3.411

Review 8.  TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases.

Authors:  Philip Chiu-Tsun Tang; Alex Siu-Wing Chan; Cai-Bin Zhang; Cristina Alexandra García Córdoba; Ying-Ying Zhang; Ka-Fai To; Kam-Tong Leung; Hui-Yao Lan; Patrick Ming-Kuen Tang
Journal:  Front Med (Lausanne)       Date:  2021-02-25

9.  Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS.

Authors:  Sophie Doublier; Cristina Zennaro; Luca Musante; Tiziana Spatola; Giovanni Candiano; Maurizio Bruschi; Luca Besso; Massimo Cedrino; Michele Carraro; Gian Marco Ghiggeri; Giovanni Camussi; Enrico Lupia
Journal:  PLoS One       Date:  2017-11-20       Impact factor: 3.240

Review 10.  Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Authors:  Carolina Lavoz; Sandra Rayego-Mateos; Macarena Orejudo; Lucas Opazo-Ríos; Vanessa Marchant; Laura Marquez-Exposito; Antonio Tejera-Muñoz; Juan F Navarro-González; Alejandra Droguett; Alberto Ortiz; Jesús Egido; Sergio Mezzano; Raúl R Rodrigues-Diez; Marta Ruiz-Ortega
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.